Kurs & Likviditet
Kalender
2024-11-07 | Kvartalsrapport 2024-Q3 |
2024-08-15 | Kvartalsrapport 2024-Q2 |
2024-05-16 | Kvartalsrapport 2024-Q1 |
2024-03-21 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2024-03-20 | Årsstämma |
2024-02-27 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-03-30 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2023-03-29 | Årsstämma |
2023-03-02 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Kvartalsrapport 2022-Q2 |
2022-05-12 | Kvartalsrapport 2022-Q1 |
2022-05-09 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2022-04-06 | Årsstämma |
2022-03-10 | Bokslutskommuniké 2021 |
2021-11-11 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Kvartalsrapport 2021-Q2 |
2021-05-12 | Kvartalsrapport 2021-Q1 |
2021-04-16 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2021-04-15 | Årsstämma |
2021-03-11 | Bokslutskommuniké 2020 |
2020-11-12 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Kvartalsrapport 2020-Q2 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-04-03 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2020-04-02 | Årsstämma |
2020-03-12 | Bokslutskommuniké 2019 |
2019-11-14 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-04-05 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2019-04-04 | Årsstämma |
2019-03-07 | Bokslutskommuniké 2018 |
2018-11-15 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Kvartalsrapport 2018-Q1 |
2018-04-20 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2018-04-19 | Årsstämma |
2018-03-07 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Kvartalsrapport 2017-Q1 |
2017-04-06 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2017-04-05 | Årsstämma |
2017-03-15 | Bokslutskommuniké 2016 |
2016-11-09 | Kvartalsrapport 2016-Q3 |
2016-08-25 | Kvartalsrapport 2016-Q2 |
2016-05-18 | Kvartalsrapport 2016-Q1 |
2016-04-20 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2016-04-19 | Årsstämma |
2016-03-16 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-28 | Kvartalsrapport 2015-Q2 |
2015-05-22 | Kvartalsrapport 2015-Q1 |
2015-04-22 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2015-04-21 | Årsstämma |
2015-03-12 | Bokslutskommuniké 2014 |
2014-11-07 | Kvartalsrapport 2014-Q3 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Kapitalmarknadsdag 2014 |
2014-04-29 | Kvartalsrapport 2014-Q1 |
2014-04-29 | Årsstämma |
2014-03-21 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2014-03-20 | Bokslutskommuniké 2013 |
2013-11-15 | Kvartalsrapport 2013-Q3 |
2013-08-29 | Kvartalsrapport 2013-Q2 |
2013-05-15 | Kvartalsrapport 2013-Q1 |
2013-04-30 | Årsstämma |
2013-04-30 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2013-03-14 | Bokslutskommuniké 2012 |
2012-11-29 | Kapitalmarknadsdag 2012 |
2012-04-26 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2012-04-25 | Årsstämma |
2011-11-17 | Kvartalsrapport 2011-Q3 |
2011-10-25 | Kapitalmarknadsdag 2011 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-05-12 | Kvartalsrapport 2011-Q1 |
2011-04-29 | X-dag ordinarie utdelning ZEAL 0.00 DKK |
2011-04-28 | Årsstämma |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Bioteknik |
Company announcement – No. 32/ 2021
Zealand Pharma to participate in Jefferies Virtual Healthcare Conference
Copenhagen, DK and Boston, MA, U.S. May 26, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company aspiring to change lives through the development of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies Virtual Healthcare Conference.
Jefferies Virtual Healthcare Conference |
Date: Wednesday, June 2, 2021 |
Presentation: 2:00 p.m. ET/ 7:00 p.m. CET |
A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
For further information, please contact:
Zealand Pharma Investor Relations
Claudia Styslinger |
Argot Partners |
investors@zealandpharma.com |
Zealand Pharma Media Relations
David Rosen |
Argot Partners |
media@zealandpharma.com |